In a controlled secondary prevention trial of estrogen and cholesterol-lowering drugs on 570 veterans, all of whom had had one or more episodes of acute myocardial infarction, changes in serum cholesterol were followed for at least five years. The Jtune 27, 1974. prophylactically effective, either for primary (in persons with no manifest CHD) or secondary (in persons with evidence of CHD) prevention. Furthermore, while it was assumed that the lower rate of CHD in middle-aged women was due to their natural estrogens, it was not clear if treatment with these steroids would be therapeutically useful for men recovered from an infarct. The primary objective of the VA Drug-Lipid Study was to assess the long-term efficacy and safety of the use of estrogen, dextrothyroxine, and aluminum nicotinate, and combinations of each of the latter two drugs with estrogen, in men with proven myocardial infarction. The central hypothesis of this trial was that lowering the serum cholesterol level might result in a reduction of the incidence of events associated with CHD in men with myocardial infarction. Therefore, the study protocol provided for detailed monitoring of serum cholesterol levels throughout the trial. The effects of treatment on cardiovascular mortality and C9ircuulation, Volumie .50, November 1974 998
2) Aluminum nicotinate, 4 g/day, resulted in a 20% reduction in cholesterol level for about 21/2 years after which levels slowly rose to a level 12% below the baseline level in good adherers; poor adherers had smaller ultimate changes.
3) Dextrothyroxine, 4 mg/day, had a sustained cholesterol-lowering effect of approximately 7Tc throughout the study.
The above values were obtained after adjusting for an underlying upward trend in all cholesterol values during the five-year observation period.
4) Discontinuation of both aluminum nicotinate and dextrothyroxine resulted in a significant rise in cholesterol within three months.
3) The 6% rise in the cholesterol level found in the control group over five years of follow-up could be attributed to aging and laboratory drift. 6) Regression toward the mean rather than pharmacological effect accounted for the greater response to treatment of patients wxith high initial cholesterol.
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Estrogen Double-blind design THE VA Drug-Lipid Study was designed as a clinical trial of secondary prevention of coronary heart disease. In 1962, when the study began, an association between high serum cholesterol and increased risk of coronary heart disease (CHD) had been established, but it was not clear whether treatment of hypercholesterolemia would be morbidity is the subject of a separate report.* This report is restricted, however, to presentation of the findings on long-term effects of these drugs on serum cholesterol, as well as a description of the methodology required in a program monitoring serum cholesterol over several years. Salient features of the study are described below. Materials and Methods Between February 1963 and August 1966, 570 male patients entered the study from 26 cooperating VA Hospitals, under a common protocol. The ages of these men ranged between 28 and 75; 95% were between 38 and 70 years. The average age was 51 yr. Ninety-two percent of the men were white. The infarction on the basis of which the patient was entered into the study was the first in 83% of the cases and the second in 15%. Two percent of the patients had had more than two infarcts at entry. Fifty-six percent of the patients entered the study between 1 and 3 months after their most recent infarct; the rest entered between 4 and 16 months postinfarction.
The patients were randomly assigned to six regimens in the following way. Approximately one-quarter of the patients was assigned to each of the following: 1) placebo; 2) estrogen; 3) a cholesterol-lowering agent; or 4) a cholesterollowering agent plus estrogen. Groups 3 and 4 were split: half was given aluminum nicotinate and half was given dextrothyroxine as the cholesterol-lowering agent. This design was used to ensure that in the final comparisons there would be comparable numbers of subjects when evaluating the effects of estrogen alone, cholesterol-lowering agent alone, and the combination of each cholesterol-lowering agent with estrogen. Figure 1 shows the distribution of the average pretreatment cholesterol values, referred to as baseline from here on. The distribution centered about 241 mg/100 ml, the mean baseline value, and it was skewed to the right, the median being 236 mg/100 ml. For each subject the standard deviation (SD) was calculated for the three pretreatment values. The mean for these standard deviations was 11.5.
In spite of random allocation to the treatments, the baseline cholesterol values of the six groups were not as close as might be desired. The average values and the 95% confidence limits (x t 1.96 SE) are as follows: placebo (P), 242 ± 7.6; estrogen (E), 233 + 7.6; aluminum nicotinate (N), 246 ± 10.6; dextrothyroxine (T), 234 ± 9.8; E + N, 245 ± 10.6; E + T 255 ± 15.5. From here on, all effects on cholesterol will be measured as percent change from baseline of the respective group.
The relationship between age and cholesterol at baseline was inverse. In a simple regression analysis of cholesterol on age, it was found that a good fit was obtained to a straight line with a significant negative slope (b = -0.71). The data points in figure 2 represent average baseline cholesterol values for the study population divided by age into six groups which were of comparable size. The elevated cholesterol level the younger coronary patients suggest a relation The five-year changes in cholesterol level for the six regimens are shown in figure 3 , which includes patients who remained in the study for the entire fiveyear follow-up. The effect of estrogen (E) on levels of total serum cholesterol was similar to that of placebo. Similarly, the addition of estrogen to d-thyroxine (E + T) and to aluminum nicotinate (E + N) had little effect on the total cholesterol-lowering capacity of either drug. For the purposes of further analysis of the cholesterol data, patients treated with placebo and estrogen were grouped together and used as controls for groups resulting from the merging of the two aluminum nicotinate regimens (N and E + N) and the two dextrothyroxine regimens (T and E + T). Figure 4 shows the cholesterol responses of these three principal groups. Aluminum nicotinate had a greater effect on cholesterol levels than dextrothyroxine with a 17% immediate fall that was maintained for six months. The reduction with dextrothyroxine was only half that achieved with nicotinate for the first six months, after which all cholesterol responses, control and treatment, rose gradually throughout the five years. At the end of the study cholesterol levels had been lowered in the aluminum nicotinate group by 4%, and in the dextrothyroxine group, by 1%, while the control group's level (P + E) was 6% higher than the levels at entry. Mean percent change in serum cholesterol from the baseline average for the six treatment cohorts followed for 60 months. E = estrogen; P = placebo; T = dextrothyroxine; N = aluminum nicotinate.
-25 L 0 1-4-7-10-13-16-19- Mean percent change in serum cholesterol from the baseline average for cohorts and for all patients. Figure 6 shows the effect of each drug alone, after the rising trend had been adjusted for. The average reduction over the entire five-year period was 6.5% for dextrothyroxine and 12.6 for aluminum nicotinate. The reduction in cholesterol level from the use of dextrothyroxine was maintained steadily throughout the study, while the more marked initial effect of aluminum nicotinate decreased slowly after two years.
Effects of Adherence
To clarify the apparent "escape" phenomenon in the aluminum nicotinate group, the influence of adherence to the prescribed regimen was evaluated. Of the 85 patients in the aluminum nicotinate cohorts, 31 were good adherers, that is, they took at least 75% of the dose for 75% or more of the time. Figure 7 shows that in the good adherers reduction of original specimens, which were stored frozen, were retested in one run at the end of the study; the results are shown by the dotted line in figure 8 . It is often said that lipid-lowering agents or diet have a greater effect on patients with high initial values. This appeared to be true in our study. However, adjustment for the effect of regression toward the mean as observed in the control group eliminated most of the apparent differences. Figure 9 shows the response to aluminum nicotinate for the patients in three groups -those with high initial values (greater than or equal to 250 mg/100 ml), those with middle range values (213-249 mg/100 ml), and those with low values (less than or equal to 212 mg/100 ml). In part a of the figure, the response of the high group appears much greater than the response for the low group. Part b of the figure shows the high, medium, and low group trends for the placebo-treated group. Here the high group shows a downward tendency and the low group values tend to rise, reflecting the regression toward the mean effect. Part c is the graph of the drug effects for the high, middle, Apparent effect and net effect of aluminum nicotinate on serum cholesterol when cholesterol is classified according to high, middle and lowt initial levels, for the cohort followed for 60 months. and low groups after adjustment for the regression toward the mean. In this part of the figure, there is virtually no difference in the percentage response to nicotinate whether the cholesterol values were initially high or low.
Discussion
The VA Drug-Lipid Study was the first of the longterm secondary prevention efforts of CHD with cholesterol-lowering drugs. At the time when the study was planned, aluminum nicotinate and dextrothyroxine were the drugs best known to have a cholesterol-lowering effect. Since clofibrate and cholestyramine became available later, they did not become part of the study. Earlier secondary prevention drug studies dealt exclusively with estrogen6`8 but at the time this study was begun the effectiveness of estrogen was still controversial. Since 1963, other 1960 and 1965 . In that study, the average net reduction in cholesterol was 12% over the 5-year period of follow-up. The other large controlled dietary study'9 was conducted in Oslo and began in 1958-60, also for a five-year follow-up period. This study reported an average net reduction of 14% due to diet. Thus the cholesterol reduction obtained in the VA study with dextrothyroxine was about the same as the results found in the clofibrate studies, while the effects of aluminum nicotinate matched what was found in the dietary studies.
From a methodological point of view, it was found to be very important to include a concurrent control group in this type of clinical drug trial. Without taking into account the changes occurring in the control group, interpretation of changes in the treatment groups might be erroneous. This was true in our own study where, in order to evaluate the true effect of the drugs, the changes occurring without the cholesterollowering drug (control group) had to be assessed. The method used was subtraction of the percent change found in the controls from the percent change in each treatment group, thus obtaining a more valid treatment effect. The adjustment procedure is particularly applicable when the treatment groups are subdivided according to initial levels and a larger response to treatment is observed in subgroups with higher initial values. If adjustment according to tendencies noted in the control eliminates the differential response, the phenomenon is due to ordinary regression toward the mean. Although this phenomenon is well known to many investigators, clinicians and drug companies often fail to acknowledge its effects and interpret improvement in those with higher initial levels as if it were due to a greater treatment effect.
In addition to relating treatment effects to control values, future study designs should use a more uniform method of expressing cholesterol changes as percent of baseline so that the results of future studies of the efficacy of various cholesterol-lowering agents would be comparable.
The benefits of cholesterol-lowering therapies in respect to morbidity are presented in a separate paper. That report will also discuss the incidence of side effects and details of adherence to therapy.
